OSTX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
8.6M
-15.7%
10.2M
-15.2%
12.0M
+74.3%
6.9M
+42.2%
4.8M
R&D
6.1M
-17.4%
7.4M
-16.4%
8.8M
+134.2%
3.8M
+50.2%
2.5M
SG&A
2.5M
-11.2%
2.8M
-11.7%
3.2M
+2.1%
3.1M
+33.6%
2.3M
Operating Income
-8575612
+15.7%
-10167938
+15.2%
-11987892
-74.3%
-6879595
-42.2%
-4838728
EBITDA
-8450674
+15.9%
-10043000
+15.3%
-11862954
-75.6%
-6754657
-42.9%
-4726214
Net Income
-8632386
+17.0%
-10396831
+22.8%
-13460833
-95.7%
-6879530
-51.6%
-4536622
EPS (Basic)
$-0.20
+25.9%
$-0.27
+22.9%
$-0.35
-66.7%
$-0.21
-10.5%
$-0.19
EPS (Diluted)
$-0.20
+25.9%
$-0.27
+22.9%
$-0.35
-66.7%
$-0.21
-10.5%
$-0.19
Shares (Diluted)
43.9M
+13.5%
38.7M
-0.0%
38.7M
+21.1%
32.0M
+27.2%
25.1M
OS Therapies (OSTX) โ€” Financials